Sharon Goswami Speaks at the Federal Circuit Bar Association’s “Patent Law Year in Review 2019” Program
January 21, 2020
On January 16, Cravath partner Sharonmoyee Goswami spoke as part of the Federal Circuit Bar Association Horizon Series. Sharon spoke on a panel entitled “Patent Law: Year in Review 2019,” which covered developments in patent law with a focus on recent decisions in the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit. The panel addressed legal updates on patentability, infringement, damages, design patents and issues related to PTAB trial proceedings. Sharon also discussed recent petitions for certiorari in patent eligibility (Section 101) cases.
Related Practices & Industries
Speakers
- Photo
-
-
J.D., 2012, New York University School of LawOrder of the Coif, magna cum laude
-
B.S.E., 2009, Princeton University
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
DRIT Wins Patent Licensing Dispute
On September 18, 2018, a Delaware jury returned a unanimous verdict in favor of Cravath client DRIT LP (“DRIT”) in a patent licensing dispute with Glaxo Group Limited and Human Genome Sciences, Inc. (“GSK”). The jury found that GSK had breached the implied covenant of good faith and fair dealing when it statutorily disclaimed a U.S. patent covering GSK’s lupus drug, Benlysta® to cut off its obligation to pay royalties to DRIT on U.S. sales of Benlysta®. The case arose out of a 2008 agreement under which GSK agreed to pay Biogen Inc. royalties on sales of Benlysta® in exchange for Biogen’s rights to certain intellectual property covering the medication. In 2012, DRIT, an investment vehicle managed by Cravath client DRI Capital, purchased Biogen’s royalty stream. In April 2015, after making royalty payments to DRIT for three years, GSK voluntarily disclaimed the royalty‑bearing patent and ceased paying royalties to DRIT. The matter was tried for six days before a jury in the Delaware Superior Court.
